Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Neutral Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNYFree Report) in a report published on Monday, Benzinga reports. Cantor Fitzgerald currently has a $165.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $235.00 to $230.00 and set an outperform rating on the stock in a research note on Friday, November 3rd. Piper Sandler lifted their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $217.00 and gave the company an overweight rating in a report on Thursday, December 14th. William Blair reissued an outperform rating on shares of Alnylam Pharmaceuticals in a research note on Monday, January 8th. HC Wainwright reaffirmed a buy rating and issued a $395.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, December 15th. Finally, Wells Fargo & Company began coverage on Alnylam Pharmaceuticals in a research report on Friday, December 8th. They set an equal weight rating and a $171.00 price target on the stock. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $230.95.

Check Out Our Latest Research Report on ALNY

Alnylam Pharmaceuticals Stock Down 0.4 %

Shares of ALNY opened at $169.34 on Monday. The company has a market capitalization of $21.25 billion, a price-to-earnings ratio of -40.90 and a beta of 0.43. Alnylam Pharmaceuticals has a 52 week low of $148.10 and a 52 week high of $227.91. The stock’s 50-day moving average price is $183.67 and its 200-day moving average price is $179.31.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 30,000 shares of the stock in a transaction dated Wednesday, December 27th. The shares were sold at an average price of $195.00, for a total value of $5,850,000.00. Following the completion of the sale, the director now owns 16,029 shares in the company, valued at approximately $3,125,655. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ALNY. Asset Management One Co. Ltd. grew its holdings in Alnylam Pharmaceuticals by 2.1% in the 2nd quarter. Asset Management One Co. Ltd. now owns 49,405 shares of the biopharmaceutical company’s stock valued at $9,384,000 after buying an additional 1,027 shares in the last quarter. DnB Asset Management AS raised its stake in Alnylam Pharmaceuticals by 102.3% during the third quarter. DnB Asset Management AS now owns 51,212 shares of the biopharmaceutical company’s stock worth $9,070,000 after purchasing an additional 25,898 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 10,519 shares of the biopharmaceutical company’s stock valued at $1,998,000 after purchasing an additional 71 shares during the last quarter. Profund Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 14.2% in the 2nd quarter. Profund Advisors LLC now owns 7,729 shares of the biopharmaceutical company’s stock valued at $1,468,000 after buying an additional 959 shares during the period. Finally, International Biotechnology Trust PLC grew its stake in shares of Alnylam Pharmaceuticals by 75.1% in the 2nd quarter. International Biotechnology Trust PLC now owns 81,600 shares of the biopharmaceutical company’s stock valued at $15,499,000 after buying an additional 35,000 shares during the period. Institutional investors and hedge funds own 93.98% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Articles

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.